CALL FOR ABSTRACTS AND PROGRAM SCHEDULE

INAUGURAL AACR INTERNATIONAL MEETING

ADVANCES IN MALIGNANT LYMPHOMA:
MAXIMIZING THE BASIC-TRANSLATIONAL INTERFACE FOR CLINICAL APPLICATION

In Cooperation with the International Conference on Malignant Lymphoma (ICML)

Abstract Submission and Clinical Trials Placeholder Deadline:
Friday, April 6, 2018

Deadline to Submit Final Placeholder Clinical Trials Data:
Friday, May 4, 2018

June 22-26, 2018
Boston Marriott Copley Place | Boston, MA

Learn more at
AACR.org/Lymphoma18
#AACRLYMP18
INAUGURAL AACR INTERNATIONAL MEETING

ADVANCES IN MALIGNANT LYMPHOMA:
MAXIMIZING THE BASIC-TRANSLATIONAL INTERFACE FOR CLINICAL APPLICATION

In Cooperation with the International Conference on Malignant Lymphoma (ICML)
June 22-26, 2018
Boston Marriott Copley Place | Boston, MA

Abstract Submission and Clinical Trials
Placeholder Deadline: Friday, April 6, 2018
Deadline to Submit Final Placeholder Clinical Trials Data: Friday, May 4, 2018
Advance Registration Deadline: Friday, May 11, 2018

TABLE OF CONTENTS
2 Scientific Committees
3 Program Schedule
6 Abstract Submission Categories and Guidelines
8 Accommodations and Travel
9 Financial Support for Attendance
10 Registration/General Information
11 General Information
11 Continuing Medical Education
12 Press/Media
12 Webcasts of Sessions

SCIENTIFIC COMMITTEE CHAIR

Ari M. Melnick, MD
Gebroe Family Professor of Hematology/Oncology
Departments of Medicine and Pharmacology
Weill Cornell Medical College, New York, NY

| Continuing Medical Education (CME) Activity–AMA PRA Category 1 Credits™ available |

About the Cover Image
Illustration of a lymphoma cancer cell.
Credit: Getty Images/Science Photo Library.
DEAR AACR MEMBERS AND COLLEAGUES,

We are delighted to invite you to attend the Inaugural AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, which is being held in cooperation with the International Conference on Malignant Lymphoma (ICML). Please make plans to join us from June 22-26, 2018, in Boston for the first AACR biennial meeting on malignant lymphoma. This must-attend program will provide a unique forum for interactive discussion and brainstorming among basic scientists, translational researchers, clinical investigators, hematologists, radiotherapists, pediatric oncologists, pathologists; and computational and systems biologists, and patient-advocates about how recent advances and emerging areas of lymphoma research hold enormous potential for transforming clinical care.

The lymphoma field is advancing rapidly, thanks to the full sequencing of the lymphoma genome, the discovery of new mechanistic data explaining how mutations work, the development of targeted therapies, recognition of “pre-lymphoma” states as potential risk factors, the advent of immunotherapy, and the unique features of immune tumors. One of the primary goals of this meeting is to generate discussion among clinical and laboratory-based thought leaders in the field by the inclusion of panel discussions in each session. We hope that this novel format will be highly interactive and generate productive ideas to be used as reference points for moving the field forward.

According to the latest data from the U.S. National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, non-Hodgkin lymphoma (NHL) is the seventh most common cancer in the United States with an estimated 72,240 new cases diagnosed in 2017. More than 20,000 individuals in the U.S. alone will die from NHL in 2017. Although lower in number than NHL, an estimated 8,260 new cases of Hodgkin lymphoma (HL) will be diagnosed in the U.S. in 2017, with more than 1,000 deaths. Dramatic increases in the five-year survival rates for both NHL and HL over the past 50 years have resulted in these being considered success stories in terms of cancer survival. However, additional research and collaboration are needed in the early detection of these diseases and in the diagnosis and treatment of lymphoma to reduce the number of new cases in the U.S. and abroad. It is hoped that this meeting will provide a venue to address the global challenges and opportunities in lymphoma research.

In recent years, thanks to its President, Dr. Franco Cavalli, the AACR has had the honor of being a collaborator with the hugely successful ICML conference on Advances in Malignant Lymphoma, held every other year since 1981, in Lugano, Switzerland and draws 3,000 attendees from around the world. Because of the increasing number of AACR members working in lymphoma and related hematologic malignancies, and the rapid advances being made in this field, the AACR leadership has recognized the importance of holding this new meeting series in the U.S. that will address the urgent professional and information needs of lymphoma researchers and clinicians residing in the U.S. and abroad. We look forward to the synergies that will ensue as a result of the cooperation with our distinguished colleagues at the ICML.

This program has been developed in close collaboration with the Scientific Committee Co Chairs and the members of the Scientific Advisory Committee who represent the leading voices in all sectors of lymphoma research. We are deeply grateful to them as this outstanding conference program would not have been possible without their dedication and extraordinary expertise.

The AACR is the first and largest professional organization in the world dedicated to conquering all cancers, both solid tumors and blood cancers, and this inaugural lymphoma meeting serves as the launching point for an increased focus on lymphoma and related lymphoid malignancy programs presented by the AACR. Having witnessed the excitement and outstanding research presented at the ICML programs in Lugano, we hope that you will participate in what promises to be the first of many exciting AACR lymphoma meetings in the U.S.

Sincerely,

Michael A. Caligiuri, MD
AACR President

Margaret Foti, PhD, MD (hc)
AACR Chief Executive Officer

Ari M. Melnick, MD
Scientific Committee Chair
# SCIENTIFIC COMMITTEE COCHAIRS

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Francesco Bertoni</td>
<td>Institute of Oncology Research, Bellinzona, Switzerland</td>
</tr>
<tr>
<td>Renier J. Brentjens</td>
<td>Memorial Sloan Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>Bertrand Nadel</td>
<td>Centre d’Immunologie de Marseille-Luminy, Marseille, France</td>
</tr>
<tr>
<td>Lisa G. Roth</td>
<td>Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY</td>
</tr>
<tr>
<td>Louis M. Staudt</td>
<td>National Cancer Institute, Bethesda, MD</td>
</tr>
<tr>
<td>Christian Steidl</td>
<td>BC Cancer Agency Vancouver Center, Vancouver, BC, Canada</td>
</tr>
<tr>
<td>Karin Tarte</td>
<td>University of Rennes, Rennes, France</td>
</tr>
<tr>
<td>Thomas E. Witzig</td>
<td>Mayo Clinic College of Medicine, Rochester, MN</td>
</tr>
<tr>
<td>Wei-Li Zhao</td>
<td>Ruijin Hospital, Shanghai Institute of Hematology, Shanghai, China</td>
</tr>
</tbody>
</table>

# SCIENTIFIC ADVISORY COMMITTEE

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Riccardo Dalla-Favera</td>
<td>Columbia University Institute for Cancer Genetics, New York, NY</td>
</tr>
<tr>
<td>Jude Fitzgibbon</td>
<td>Barts Cancer Institute, London, United Kingdom</td>
</tr>
<tr>
<td>Christopher R. Flowers</td>
<td>Emory University Winship Cancer Institute, Atlanta, GA</td>
</tr>
<tr>
<td>Lee M. Greenberger</td>
<td>The Leukemia &amp; Lymphoma Society, Rye Brook, NY</td>
</tr>
<tr>
<td>Ricky W. Johnstone</td>
<td>Peter MacCallum Cancer Centre, Melbourne, VIC, Australia</td>
</tr>
<tr>
<td>Ronald Levy</td>
<td>Stanford University, Stanford, CA</td>
</tr>
<tr>
<td>Tak W. Mak</td>
<td>Campbell Family Institute for Breast Cancer Research, Toronto, ON, Canada</td>
</tr>
<tr>
<td>Kristy L. Richards</td>
<td>Cornell University, Ithaca, NY</td>
</tr>
<tr>
<td>David M. Weinstock</td>
<td>Dana-Farber Cancer Institute, Boston, MA</td>
</tr>
<tr>
<td>Anas Younes</td>
<td>Memorial Sloan Kettering Cancer Center, New York, NY</td>
</tr>
</tbody>
</table>
FRIDAY, JUNE 22

Welcome and Opening Keynote Addresses
6:00 p.m.-8:00 p.m.

Welcome from AACR Chief Executive Officer
Margaret Foti, American Association for Cancer Research, Philadelphia, PA

Welcome from the Scientific Committee Chair
Ari M. Melnick, Weill Cornell Medical College, New York, NY

Keynote Address: Immunogenicity Predicts Prevention
Michael A. Caligiuri, City of Hope National Medical Center, Los Angeles, CA

Keynote Address
Carl H. June, University of Pennsylvania, Philadelphia, PA

Panel Discussion
Ari M. Melnick
Michael A. Caligiari
Carl H. June

Opening Reception
8:00 p.m.-10:00 p.m.

SATURDAY, JUNE 23

Continental Breakfast
7:00 a.m.-8:00 a.m.

Concurrent Sessions 1-2
7:15 a.m.-8:00 a.m.

Concurrent Session 1: Canine Lymphoma as a Surrogate for Human Lymphomas: What Can We Learn from Canine Clinical Trials?
Session Cochairs: Luca Aresu, University of Turin, Grugliasco, Italy, and Kristy L. Richards, Cornell University, Ithaca, NY

Panel Discussion
Luca Aresu
Kristy L. Richards
Cheryl A. London, Tufts Medical Center, Boston, MA
Laura Marconato, Centro Oncologico Veterinario, Sasso Marconi, Italy

Concurrent Session 2: What Is the Optimal Therapeutic Approach to NHL in Adolescents and Young Adults? A Discussion from the Pediatric and Adult Perspectives
Session Chair: Lisa G. Roth, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY

Panel Discussion
Lisa G. Roth
Kieron Dunleavy, George Washington University, Washington, DC

Plenary Session 1: Are We Ready for Lymphoma MATCH Trials?
8:00 a.m.-10:30 a.m.
Session Chair: Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY

Precision medicine based on the genetic taxonomy of DLBCL
Louis M. Staudt, National Cancer Institute, Bethesda, MD

How to design a MATCH trial for lymphoma
Anas Younes

Molecular typing in DLBCL: Sub-set and match?
Peter W. M. Johnson, University of Southampton, Southampton, United Kingdom
Additional speaker to be announced

Panel Discussion
Break
10:30 a.m.-11:00 a.m.

Spotlight on Proffered Papers Session 1
11:00 a.m.-11:30 a.m.

Poster Session A/Lunch
11:45 a.m.-1:45 p.m.

Plenary Session 2: Targeting the Epigenome of DLBCL
2:00 p.m.-4:00 p.m.
Session Cochairs: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland and Laura Pasqualucci, Columbia University Institute for Cancer Genetics, New York, NY

DNA and histone methylation as therapeutic targets in lymphoma
Ari M. Melnick, Weill Cornell Medical College, New York, NY

Title to be announced
Vincent Ribrag, Institut Gustave Roussy, Villejuif, France

Germinal center-derived lymphomas: At the intersection of genetics and epigenetics
Laura Pasqualucci

BET inhibitors in lymphoma
Francesco Bertoni

Panel Discussion
Break
4:00 p.m.-4:30 p.m.
Plenary Session 3: Can Liquid Biopsies Replace Tissue and Be Used to Guide Clinical Decisions?  
4:30 p.m.-6:30 p.m.  
Session Chair: Davide Rossi, Università degli Studi del Piemonte Orientale, Vercelli, Italy

Circulating tumor DNA to monitor treatment response and detect resistant clones in indolent lymphoproliferative diseases treated with novel therapies  
Constantine S. Tam, Peter MacCallum Cancer Center, East Melbourne, Australia

Tumor fingerprints in the liquid biopsy: Immunoglobulin gene rearrangement or CAPP-seq?  
Wyndham H. Wilson, National Cancer Institute, Bethesda, MD

Title to be announced  
Davide Rossi  
Panel Discussion  
Dinner on Own  
6:30 p.m.

SUNDAY, JUNE 24

Continental Breakfast  
7:00 a.m.-8:00 a.m.

Concurrent Sessions 3-4  
7:15 a.m.-8:00 a.m.

Concurrent Session 3: What Is the Current Role and Impact of CRISPR Screening to Define Therapeutic Targets in Lymphoma?  
Session Chair: Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, New York, NY

Michael T. Hemann, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge  
SandDeep S. Dave, Duke University, Durham, NC  
Hans-Guido Wendel

Concurrent Session 4: Genetic and Molecular Heterogeneity between Western and Asian Lymphoma Patients  
Session Chair: Wei-Li Zhao, Ruijin Hospital, Shanghai Institute of Hematology, Shanghai, China

Panel Discussion  
Wei-Li Zhao  
Qiang Pan-Hammarström, Karolinska Institute, Stockholm, Sweden  
Davide Rossi, Università degli Studi del Piemonte Orientale, Vercelli, Italy

Plenary Session 4: Will CAR T Cells Replace BMT as a Modality for NHL?  
8:00 a.m.-10:30 a.m.  
Session Chair: Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, NY

Title to be announced  
Craig S. Sauter, Memorial Sloan Kettering Cancer Center, New York, NY

Title to be announced  
Michael R. Bishop, University of Chicago, Chicago, IL  
Next-gen T cells  
Renier J. Brentjens  
Additional speaker to be announced  
Panel Discussion  
Break  
10:30 a.m.-11:00 a.m.

Spotlight on Proffered Papers Session 2  
11:00 a.m.-11:30 a.m.

Poster Session B/Lunch  
11:45 a.m.-1:45 p.m.

Plenary Session 5: The Significance of Targeting the Microenvironment in Lymphoma  
2:00 p.m.-4:00 p.m.  
Session Chair: Karin Tarte, University of Rennes, Rennes, France

Ex vivo lymphoid tissue microenvironments to model epigenetics and signaling in healthy and malignant B cells  
Ankur Singh, Cornell University, Ithaca, NY

Dissecting microenvironmental cues that promote B cell lymphoma growth in secondary lymphoid organs  
Uta Höpken, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

Targeting cancer-associated fibroblasts to promote antitumor immunity  
Hélène Salmon, Icahn School of Medicine at Mount Sinai, New York, NY

Panel Discussion

Break  
4:00 p.m.-4:30 p.m.

Plenary Session 6: Follicular Lymphoma: When to Treat and How to Define Early Disease  
4:30 p.m.-6:30 p.m.  
Session Chair: Bertrand Nadel, Centre d’Immunologie de Marseille-Luminy, Marseille, France

Title to be announced  
Bertrand Nadel  
Title to be announced  
Gilles Salles, Lyon-Sud Charles Mérieux Medical School, Pierre Bénite, France

Frontline chemotherapy-free treatments for follicular lymphoma?  
Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland  
Additional speaker to be announced  
Panel Discussion  
Dinner on Own  
6:30 p.m.
MONDAY, JUNE 25

Continental Breakfast
7:00 a.m.-8:00 a.m.

Concurrent Sessions 5-6
7:15 a.m.-8:00 a.m.

Concurrent Session 5: What Is the Molecular Basis and Most Promising Road towards Molecular Targeted Therapies for Double-Hit Lymphoma?
Session Chair: David M. Weinstock, Dana-Farber Cancer Institute, Boston, MA
Title to be announced
David M. Weinstock
Title to be announced
Philippe Armand, Dana-Farber Cancer Institute, Boston, MA
Panel Discussion
Concurrent Session 6: What Do Mutation Profiles Teach Us about Rare versus Common Forms of Lymphoma?
Session Chair: Sandeep S. Dave, Duke University, Durham, NC
Rare vs. common: Using genomic discoveries for a unified view of lymphoma
Sandeep S. Dave
Additional speaker to be announced
Panel Discussion

Plenary Session 7: How Do Clonal Dynamics and Tumor Heterogeneity Factor into Clinical Outcome and Therapy?
8:00 a.m.-10:30 a.m.
Session Chair: Dan A. Landau, Weill Cornell Medical College, New York, NY
Speakers to be announced
Panel Discussion

Break
10:30 a.m.-11:00 a.m.

Spotlight on Proffered Papers Session 3
11:00 a.m.-11:30 a.m.

Poster Session C/Lunch
11:45 a.m.-1:45 p.m.

Plenary Session 8: What Is the Role for Checkpoint Protein Functionality and Therapeutic Blockade in Lymphoma?
2:00 p.m.-4:00 p.m.
Session Chair: Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA
Title to be announced
Margaret A. Shipp
Title to be announced
Ronald Levy, Stanford University, Stanford, CA
Exploiting epigenetic and immune vulnerabilities in lymphoma
Ricky W. Johnstone, Peter MacCallum Cancer Centre, Melbourne, Australia
Panel Discussion

Break
4:00 p.m.-4:30 p.m.

Plenary Session 9: How Can We Improve the Outcome of Patients with PTCL?
4:30 p.m.-6:30 p.m.
Session Chair: Kerry Savage, University of British Columbia, Vancouver, BC, Canada
How do we raise the therapeutic bar in PTCLs?
Kerry Savage
PDX models in T-cell lymphoma
David M. Weinstock, Dana-Farber Cancer Institute, Boston, MA
Novel drug combinations
Neha Mehta-Shah, Washington University Medical School, St. Louis, MO
Additional speaker to be announced
Panel Discussion
Dinner on Own
6:30 p.m.

TUESDAY, JUNE 26

Continental Breakfast
7:00 a.m.-8:00 a.m.

Keynote Address
8:00 a.m.-9:15 a.m.
Title to be announced
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX
Panel Discussion

Break
9:15 a.m.-9:30 a.m.

Plenary Session 10: Transforming First-Line Therapy for Hodgkin and Non-Hodgkin Lymphoma
9:30 a.m.-12:00 p.m.
Session Chair: Thomas E. Witzig, Mayo Clinic College of Medicine, Rochester, MN
Speakers to be announced
Meeting Highlights: Promise for the Future
12:00 p.m.-12:30 p.m.
Ari M. Melnick, Weill Cornell Medical College, New York, NY
When submitting an abstract for the Inaugural AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application using the Online Abstract Submission System, authors will be asked to choose the appropriate category below that best describes the scientific content of the abstract. This information will be used as a guide by the members of the Scientific Committee in their review of abstracts.

- **Lymphoid Cancers**
  - Hodgkin
  - Non-Hodgkin
  - Non-Hodgkin (Pediatric, Adolescent, and Young Adult)
  - Chronic Lymphocytic Leukemia (CLL)
  - Multiple Myeloma
  - Canine Lymphoma as a Surrogate
  - Other

- **Basic and Translational Science**
  - Bioinformatics, computational and systems biology
  - Genetics and epigenetics
  - Risk models: Genetic
  - Risk models: Immune deficiencies
  - Genomics, epigenomics, and other -omics
  - Patient-derived xenograft (PDX) models
  - Tumor biology and heterogeneity
  - Other

- **Diagnostic and Prognostic Biomarkers**

- **Ethnicity as a Risk Factor in Cancer Disparities**

- **Imaging and Early Detection**

- **Therapeutics and Clinical Trials in Lymphoma**
  - Chemotherapy and molecular targeted therapies
  - Radiation therapy
  - Immunotherapy
  - Combination therapies
  - Stem cell transplant
  - Targeting the tumor microenvironment
  - Trials in Progress
  - Other

- **Late Effects in Lymphoma Survivors**

- **Pathology and Classification of Lymphomas**

- **Prevention and Cancer Interception**

- **Other**

**GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS**

(Submission deadline: 11:59 p.m. U.S. Eastern Time, Friday, April 6, 2018)

Content of Abstracts. Authors who submit abstracts confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the Inaugural AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application. Each abstract should contain: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.

Authors must accept sole responsibility for the statements in their abstracts. Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to *Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition* (Council of Science Editors, 2014).
Copyright Transfer/Abstract Presentation/Sponsor Permission.
On behalf of all authors, the corresponding author must:
- Transfer copyright of the abstract to the AACR for publication; and
- Confirm that an author will attend the Inaugural AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application to present the abstract

Abstract Control Number. An Abstract Control Number (e.g., 17-A-1234-AACR) will be assigned to each abstract submitted and will be listed on all email correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.

Financial Relationships of Coauthors. Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships of all of your coauthors. For more information on financial relationships, visit AACR.org/cme.

Length of Abstracts. The combined length of the abstract body, title, and tables may not exceed 2,600 characters, not including spaces and the author string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit.

Disclosure of Chemical Structures. At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids co-crystallized with low-molecular-weight molecules. If chemical compounds were used, the corresponding author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the meeting. The chemical structures are not required to be included at the time of abstract submission; rather, an indication of the intent to disclose any such structures at the time of presentation is required. The Scientific Committee will then evaluate the information provided by the corresponding author and determine the acceptability of the proffered paper for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for participation; however, a limited number of these abstracts may be accepted for presentation if deemed to be of sufficient scientific merit.

Deadline for Withdrawal of Abstracts. The AACR cannot comply with any request for withdrawal of an abstract that will delay the publication of the Program. However, requests to withdraw abstracts will be accepted through Friday, May 25, 2018. Withdrawal requests must be sent by email to abstract@aacr.org. Withdrawal requests must include the abstract control number and title as well as an explanation of the reason for withdrawal.

Opportunities for Short Talks from Abstracts. The Scientific Committee will evaluate highly rated abstracts and where thematically appropriate, invite authors to present a short talk during the program. All accepted abstracts are eligible. Not all sessions will include short talks.

Release Date for Abstracts. All accepted abstracts are scheduled to be posted online via the conference itinerary planner and app on Friday, June 8. Abstracts will not be available before this date.

Presentation of Abstracts. Every abstract that has been accepted for publication in the online Proceedings must also be presented at the meeting. Specifically, the author listed as the presenter must register for the meeting and attend the session in which the abstract is scheduled to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to present the abstract, he or she must contact the AACR Program Development Department to designate a coauthor to serve as the presenter. If no authors are available to present the abstract, the presenter must withdraw the abstract by submitting a withdrawal request by email to abstract@aacr.org. Withdrawal requests must include the abstract control number and title as well as an explanation of the reason for withdrawal.

Clinical Trials and Placeholder Abstract Deadline All abstracts describing clinical trials, including trials in progress, should be submitted by the Friday, April 6 deadline using the Therapeutics and Clinical Trials in Lymphoma category or the Placeholder: Clinical Trials in Lymphoma category. Except for Trials in Progress, abstracts may be submitted under the Placeholder: Clinical Trials in Lymphoma category with the objectives of the study, methodology, and preliminary data or an indication of the type of results anticipated. The full abstract, including final results and conclusions, is due Friday, May 4.

Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:
- The withdrawal of the abstract from the session
- The removal of the abstract from the online Proceedings
- The loss of future abstract submission/authorship privileges for the presenter of the abstract

Best Poster Prizes
All abstracts accepted for poster presentation at the meeting will be eligible for one of three “Best Poster Prizes” selected by a subcommittee comprised of members of the Scientific Committee. Posters will be judged based on their scientific merit, relevance, clarity, and overall presentation. Awardees will be provided with complimentary registration to the Second AACR International Meeting Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application to be held in June 2020.
ACCOMMODATIONS AND TRAVEL

The conference will be held at the Boston Marriott Copley Place, set in the heart of downtown and just 10 miles/19 km from Boston Logan Airport.

A reduced conference rate of USD 289.00 per night (plus taxes and fees) is available to conference attendees until Thursday, May 31, 2018. Hotel reservations can be made online or by phone. After May 31, reservations and rates will be subject to hotel availability. Room reservations must be guaranteed with a major credit card. To make a reservation, please visit the Accommodations and Travel webpage at www.AACR.org/Lymphoma18.

LOCATION

The city of Boston provides a rich historical backdrop to the Inaugural Advances in Malignant Lymphoma Meeting. From America’s history found along the Freedom Trail, to world-famous museums, international cuisine, and shopping options, the location offers convenience and value for all attendees.

TRAVEL TO BOSTON

The closest major airport to the Boston Marriott Copley Place is Boston Logan Airport (BOS), located approximately 10 miles away (15-20 minutes).

The AACR has named Gant Travel Management as its official travel coordinator for this conference. Gant will provide custom itineraries with the lowest applicable airfares and best journey time. Fly on United Airlines, the official airline of this conference, and save with special discounts exclusive to attendees and guests. Full mileage credit will be earned by frequent flyer club members.

Gant is open from 7:30 a.m. to 6:00 p.m. U.S. Central Time, Monday through Friday.

Amtrak train service is also readily available for attendees traveling from the Eastern U.S. to Boston. Amtrak’s Back Bay/ Copley Station is approximately 0.2 miles from the Boston Marriott Copley Place.

For additional information on travel to Boston and ground transportation once you arrive, please visit www.AACR.org/Lymphoma18 and follow the link for Accommodations and Travel.

INTERNATIONAL TRAVEL

If you plan to attend the Inaugural AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, please contact the American Consulate in your country to review the current regulations for travel to the United States. Obtaining the proper documentation may take several weeks or months, depending on your location, so please contact the consulate as soon as possible if you are considering attending this conference. Information is also available on the U.S. Department of State website at Travel.State.gov.
FINANCIAL SUPPORT FOR ATTENDANCE

AACR SCHOLAR-IN-TRAINING AWARDS

AACR Associate Members in good standing who submit abstracts may be considered for a Scholar-in-Training Award to offset a portion of the registration, travel, and subsistence expenses incurred in attending this conference. The number of awards provided and the dollar amounts of each award will be based on available funding. The award application deadline is Friday, April 6. Additional information and application instructions will be available online at www.AACR.org/Lymphoma18.

MEMBERSHIP

AACR Minority and Minority-Serving Institution (MMSI) Faculty Scholar in Cancer Research Awards

Full-time minority faculty and faculty of Minority-Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], American Indian Tribally-Controlled Colleges and Universities [AITCCUs], and other postsecondary institutions as defined by the U.S. Department of Education) who present a proffered paper at this conference are encouraged to apply for this meritorious scholar award. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the National Cancer Institute, the purposes of these awards are to increase the scientific knowledge base of minority faculty and faculty at MSIs, to encourage them in their research, and to assist in inspiring their students to pursue careers in cancer research. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. The award application deadline is Friday, April 6. Additional information and application instructions are available online at www.AACR.org/Lymphoma18.

AACR Minority Scholar in Cancer Research Awards

Presenters of a proffered paper who are full-time predoctoral (graduate or medical) student, residents, and clinical or postdoctoral fellows who are engaged in cancer research or have the training and potential to make contributions to this field, are encouraged to apply for this meritorious scholar award. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the National Cancer Institute, this program applies only to racial/ethnic minority groups that have been identified by the NCI as being traditionally underrepresented in cancer and biomedical research, i.e., African American/Black, Alaskan Native, Hispanic/Latino, Native American, and Native Pacific Islander. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. The award application deadline is Friday, April 6. Additional information and application instructions are available online at www.AACR.org/Lymphoma18.
REGISTRATION AND GENERAL INFORMATION

Registration will not be processed without full payment. Government or other payment orders are not accepted. All payments must be in U.S. currency, drawn on a U.S. bank. Visa, MasterCard, and American Express are also accepted for payment. Places at the conference are on a first-come, first-served basis, according to the date of registration. Onsite registration will be available at the Boston Marriott Copley Place on beginning on Friday, June 22 at 3:00 pm. All registrations are for the full conference.

Requests for refunds must be made in writing and received by Tuesday, May 22, 2018. Refund requests may be sent by email to meetings@aacr.org. There will be a $75 administrative fee for processing cancellations received by May 22. After May 22, no refunds can be made.

Individuals wishing to attend the conference can register online at www.AACR.org/Lymphoma18. Attendee registration includes admission to all scientific sessions, poster sessions, the opening reception on June 22, conference continental breakfasts on June 23, 24, 25, and 26, and coffee breaks. Registration also provides individual access to the Inaugural AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application Webcast and one complimentary drink ticket to the opening reception on June 22.

AACR membership is available to individuals who are interested in joining the AACR and being a part of a dynamic and vibrant organization that offers its members benefits, programs and activities that promote the exchange of timely scientific information and excellent opportunities to participate more fully in the global conquest of cancer by fostering important relationships and collaborations with cancer scientists internationally. The AACR is also eager to support the exchange of knowledge and research with investigators who are in countries with emerging economies. Significantly reduced membership dues are available for these investigators. Membership information and the Membership Application form can be downloaded from the AACR website at AACR.org/Membership. Contact the Membership Department at 215-440-9300 or membership@aacr.org with any questions.
CALL FOR ABSTRACTS AND PROGRAM SCHEDULE

Nonmember pre-/postdoctoral students must have their registrar, dean, or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to cancer research.

AACR MEMBERS

<table>
<thead>
<tr>
<th>Membership Type</th>
<th>Advance until May 11</th>
<th>Regular after May 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active/Affiliate</td>
<td>$800</td>
<td>$1,025</td>
</tr>
<tr>
<td>Associate/Emeritus</td>
<td>$480</td>
<td>$625</td>
</tr>
<tr>
<td>Patient Advocate</td>
<td>$250</td>
<td>$350</td>
</tr>
<tr>
<td>Student</td>
<td>$150</td>
<td>$150</td>
</tr>
</tbody>
</table>

NONMEMBERS

<table>
<thead>
<tr>
<th>Category</th>
<th>Advance until May 11</th>
<th>Regular after May 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academic, Government and not-for-Profit Institutions</td>
<td>$1,125</td>
<td>$1,285</td>
</tr>
<tr>
<td>Industry</td>
<td>$1,405</td>
<td>$1,525</td>
</tr>
<tr>
<td>Pre- and Post-doctoral Students(^1)</td>
<td>$600</td>
<td>$725</td>
</tr>
<tr>
<td>Patient Advocate</td>
<td>$350</td>
<td>$450</td>
</tr>
<tr>
<td>Spouse/Guest (No admittance to lecture sessions)</td>
<td>$200</td>
<td>$200</td>
</tr>
</tbody>
</table>

\(^1\) Nonmember pre-/postdoctoral students must have their registrar, dean, or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to cancer research.

CONTINUING MEDICAL EDUCATION (CME)

The AACR’s Continuing Medical Education (CME) Program brings the latest cancer research from “bench to bedside and back.” The AACR has been awarded Full Accreditation status from the Accreditation Council for Continuing Medical Education (ACCME). The CME Program consists of educational interventions designed to encourage the analysis and discussion of the latest findings in all areas of basic, translational, and clinical cancer research not only among researchers, but also by engaging clinicians in this scientific discourse. The AACR is committed to advance the ability of clinicians to apply critical aspects of cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer.

Continuing Medical Education Activity—AMA PRA Category 1 Credits™ will be available. Details will be available online at www.AACR.org/Lymphoma18.

Assistance for Attendees with Disabilities

This AACR conference is accessible to all registrants. Attendees with special requirements for transportation, hotel accommodations, or other facilities associated with the conference should notify the AACR in advance when registering or by emailing meetings@aacr.org.
Members of the national and international media interested in
the most up-to-date information on basic, translational, and
clinical research in lymphoma can register for the meeting by
contacting Julia Gunther at julia.gunther@aacr.org. For more
information on the press operation at the Inaugural AACR
International Meeting Advances in Malignant Lymphoma,
contact Rachel Salis-Silverman at 215-446-7159 or rachel.
silverman@aacr.org, or Julia Gunther at 215-446-6896 or
julia.gunther@aacr.org. Reporters and PIOs from cancer and
medical centers who are interested in registering for the
conference should contact Julia Gunther at julia.gunther@aacr.org. The AACR does not release media lists, but will make
available company-sponsored press releases on abstract
presentations in the press room. For more information on the
Inaugural AACR International Meeting: Advances in Malignant
Lymphoma: Maximizing the Basic-Translational Interface for
Clinical Application press program contact Julia Gunther at
215-446-6896 or julia.gunther@aacr.org.

WEBCASTS OF SESSIONS
The AACR will make a limited number of selected session
webcasts free to all interested researchers. All paid
registrants will receive exclusive online streaming access
to the audio and slides of all scientific sessions presented
at the Inaugural AACR International Meeting: Advances in
Malignant Lymphoma: Maximizing the Basic-Translational
Interface for Clinical Application.*

- Presentation slides synchronized with recorded audio
  presentations
- Speakers’ mouse movements captured and included
  in playback
- Available on compatible mobile devices and smart
  phones such as iPad, iPod Touch, and iPhone
- Presentations searchable by session title, presentation title,
  and speaker name
- Exclusive access to online content for 15 months after
  the conference

*Participation in the Inaugural AACR International Meeting: Advances in
Malignant Lymphoma: Maximizing the Basic-Translational Interface for
Clinical Application webcasts is left to the discretion of each speaker.
As a result, some presentations may not be available for webcast, and
some webinar presentations may not include all slides. Sessions will not be
streamed live. Selected session webcasts will be made available free within
24 hours; the remaining webcasts will be made available on July 17,
2018. Registrants will receive login information via email on that date.